[Immuno-Oncology Summit 2020] Driving Robust and Reproducible ADCC and T Cell Redirection with Single Donor KILR® CD16 Effector Cells
- File Name/Number:
- Immuno-Oncology Summit 2020
Success of ADCC assays is highly dependent on the quality of effector cells used. However, human primary cells (such as PBMCs or NK cells) suffer from inter-individual variability, while NK cell lines engineered to overexpress CD16, often show high background lysis in susceptible cell models, and high functional variability under different culture conditions. In this poster, we present data on cytotoxicity assays using single donor-derived, engineered effector cells to stably express CD16, the KILR CD16 Effector Cells. These uniformly manufactured cells maintain their T cell phenotype (TCRab+, CD3+ and CD8+), and have the added ability to drive ADCC through the overexpression of CD16. Importantly, multiple batches of manufactured cells demonstrate consistent CD16 expression and killing capacity, further reducing long-term variability. These cells are optimized as frozen ready-to-use cells and generate robust assay windows with excellent repeatability and precision, enabling their use for lot release and characterization studies. The results of an evaluation study with MabThera (rituximab) using the Raji model demonstrate excellent accuracy, linearity, and intermediate precision of the ADCC assay using the KILR CD16 Effector Cells. Furthermore, we demonstrate that these effector cells are compatible with T cell redirection applications, using the clinical molecule blinatumomab.
Listen to a recording of this poster by Natalie Gath.